Interaction of the Novel Antipsychotic Aripiprazole with 5-HT1A and 5-HT 2A Receptors: Functional Receptor-binding and in Vivo Electrophysiological Studies

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2007 Jan 24

PMID 17242925

Citations 51

Authors

Arlene D Stark

Shaun Jordan

Kelly A Allers

Robert L Bertekap

Ruoyan Chen

Tanaz Mistry Kannan

Thaddeus F Molski

Frank D Yocca

Trevor Sharp

Tetsuro Kikuchi

Kevin D Burris

Affiliations

Soon will be listed here.

Abstract

Background: Aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydro-2(1H)-quinolinone) is a novel antipsychotic with a mechanism of action that differs from current typical and atypical antipsychotics. Aripiprazole interacts with a range of receptors, including serotonin [5-hydroxytryptamine (5-HT)] and dopamine receptors.

Materials And Methods: This study examined aripiprazole's interactions with 5-HT systems in vitro and in vivo to further clarify its pharmacologic properties.

Results: Aripiprazole produced increases in [(35)S]GTPgammaS binding to rat hippocampal membranes. Its potency (pEC(50) = 7.2) was similar to that of ziprasidone (7.1) and greater than that of 5-HT (6.7) and buspirone (6.4), a 5-HT(1A)-receptor partial agonist, whereas its intrinsic activity was similar to that of ziprasidone and buspirone. The stimulatory effect of aripiprazole was blocked by WAY-100635, a 5-HT(1A)-receptor antagonist. In in vivo electrophysiology studies, aripiprazole produced a dose-related reduction in the firing rate of 5-HT-containing dorsal raphe neurons in rats, which was both prevented and reversed by WAY-100635 administration. Aripiprazole showed a high affinity for human 5-HT(1A) receptors (K (i) = 4.2 nM) using parietal cortex membrane preparations. In membranes from cells expressing human recombinant receptors, aripiprazole bound with high affinity to 5-HT(2A) receptors (K (i) = 3.4 nM), moderate affinity to 5-HT(2C) (K (i) = 15 nM) and 5-HT(7) (K (i) = 39 nM) receptors, and low affinity to 5-HT(6) receptors (K (i) = 214 nM) and 5-HT transporter (K (i) = 98 nM). In addition, aripiprazole potently blocked 5-HT(2A)-receptor-mediated increases in intracellular Ca(2+) levels in a rat pituitary cell line (IC(50) = 11 nM).

Discussion: These results support a partial agonist activity for aripiprazole at 5-HT(1A) receptors in vitro and in vivo, and suggest important interactions with other 5-HT-receptor subtypes. This receptor activity profile may contribute to the antipsychotic activity of aripiprazole in humans.

Citing Articles

The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy.

Sommerfeld-Klatta K, Jiers W, Rzepczyk S, Nowicki F, Lukasik-Glebocka M, Swiderski P Int J Mol Sci. 2024; 25(13).

PMID: 39000411 PMC: 11242277. DOI: 10.3390/ijms25137304.

Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal.

Iasevoli F, Avagliano C, DAmbrosio L, Barone A, Ciccarelli M, De Simone G Biomedicines. 2023; 11(3).

PMID: 36979877 PMC: 10046109. DOI: 10.3390/biomedicines11030895.

A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.

Harlin M, Yildirim M, Such P, Madera-McDonough J, Jan M, Jin N CNS Drugs. 2023; 37(4):337-350.

PMID: 36961650 PMC: 10126081. DOI: 10.1007/s40263-023-00996-8.

Agonistic properties of a series of psychotropic drugs at 5-HT receptors in rat and human brain membranes determined by [S]GTPγS binding assay.

Odagaki Y, Mikami M, Kinoshita M, Meana J, Callado L, Garcia-Sevilla J Pharmacol Rep. 2023; 75(2):266-275.

PMID: 36637685 DOI: 10.1007/s43440-023-00448-6.

Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D and Serotonin 1A and 2A Receptors in .

Jalles A, Vieira C, Pereira-Sousa J, Vilasboas-Campos D, Mota A, Vasconcelos S Biomedicines. 2022; 10(2).

PMID: 35203579 PMC: 8962381. DOI: 10.3390/biomedicines10020370.

References

Zhang J, Kowal D, Nawoschik S, Lou Z, Dunlop J . Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2005; 71(4):521-9. DOI: 10.1016/j.bcp.2005.11.007. View

Bardin L, Kleven M, Barret-Grevoz C, Depoortere R, Newman-Tancredi A . Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology. 2005; 31(9):1869-79. DOI: 10.1038/sj.npp.1300940. View

Lieberman J, Mailman R, Duncan G, Sikich L, Chakos M, Nichols D . Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 1998; 44(11):1099-117. DOI: 10.1016/s0006-3223(98)00187-5. View

Andrade R . Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Ann N Y Acad Sci. 1999; 861:190-203. DOI: 10.1111/j.1749-6632.1998.tb10191.x. View

Shapiro D, Renock S, Arrington E, Chiodo L, Liu L, Sibley D . Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8):1400-11. DOI: 10.1038/sj.npp.1300203. View

Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y . 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995; 274(1):329-36. View

VanderMaelen C, Matheson G, Wilderman R, Patterson L . Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol. 1986; 129(1-2):123-30. DOI: 10.1016/0014-2999(86)90343-2. View

Millan M . Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000; 295(3):853-61. View

Hajos M, Hajos-Korcsok E, Sharp T . Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol. 1999; 126(8):1741-50. PMC: 1565963. DOI: 10.1038/sj.bjp.0702510. View

10.

Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A . Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005; 1043(1-2):32-41. DOI: 10.1016/j.brainres.2005.02.072. View

11.

Varty G, Bakshi V, Geyer M . M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology. 1999; 20(4):311-21. DOI: 10.1016/S0893-133X(98)00072-4. View

12.

Stockmeier C, DiCarlo J, Zhang Y, Thompson P, Meltzer H . Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther. 1993; 266(3):1374-84. View

13.

Marder S, McQuade R, Stock E, Kaplita S, Marcus R, Safferman A . Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003; 61(2-3):123-36. DOI: 10.1016/s0920-9964(03)00050-1. View

14.

Ceci A, Baschirotto A, Borsini F . The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology. 1994; 33(5):709-13. DOI: 10.1016/0028-3908(94)90177-5. View

15.

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

16.

Potkin S, Saha A, Kujawa M, Carson W, Ali M, Stock E . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60(7):681-90. DOI: 10.1001/archpsyc.60.7.681. View

17.

Keck Jr P, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A . A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9):1651-8. DOI: 10.1176/appi.ajp.160.9.1651. View

18.

Burris K, Molski T, Xu C, Ryan E, Tottori K, Kikuchi T . Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002; 302(1):381-9. DOI: 10.1124/jpet.102.033175. View

19.

Kane J, Carson W, Saha A, McQuade R, Ingenito G, Zimbroff D . Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63(9):763-71. DOI: 10.4088/jcp.v63n0903. View

20.

Blier P, De Montigny C . Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1987; 1(5):470-80. DOI: 10.1002/syn.890010511. View